Omnicell draws $150 million under revolver for 340B Link purchase

By Sara Rosenberg

New York, Aug. 12 – Omnicell Inc. borrowed $150 million under its existing $500 million revolving credit facility to help fund the acquisition of Pharmaceutical Strategies Group’s 340B Link business, according to an 8-K filing with the Securities and Exchange Commission.

Other funds for the $225 million acquisition will come from available cash on the company’s balance sheet, according to a press release.

Closing is expected this year, subject to Hart-Scott-Rodino clearance and the other customary conditions.

Omnicell is a Mountain View, Calif.-based provider of medication management solutions and adherence tools for health systems and pharmacies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.